Risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in intellectual disability: randomised controlled trial

dc.contributor.authorTyrer, Peter
dc.contributor.authorOliver-Africano, Patricia C
dc.contributor.authorAhmed, Zed
dc.contributor.authorBouras, Nick
dc.contributor.authorCooray, Sherva
dc.contributor.authorDeb, Shoumitro
dc.contributor.authorMurphy, Declan
dc.contributor.authorHare, Monica
dc.contributor.authorMeade, Michael
dc.contributor.authorReece, Ben
dc.contributor.authorKramo, Kofi
dc.contributor.authorBhaumik, Sabyasachi
dc.contributor.authorHarley, David
dc.contributor.authorRegan, Adrienne
dc.contributor.authorThomas, David
dc.contributor.authorRao, Bharti
dc.contributor.authorNorth, Bernard
dc.contributor.authorEliahoo, Joseph
dc.contributor.authorKaratela, Shamshad
dc.contributor.authorSoni, Anju
dc.contributor.authorCrawford, Mike
dc.date.accessioned2015-12-07T22:14:01Z
dc.date.issued2008
dc.date.updated2015-12-07T07:22:34Z
dc.description.abstractBackground: Aggressive challenging behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared flexible doses of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second-generation antipsychotic), and placebo, in the treatment of this behaviour. Methods: 86 non-psychotic patients presenting with aggressive challenging behaviour from ten centres in England and Wales, and one in Queensland, Australia, were randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29). Clinical assessments of aggression, aberrant behaviour, quality of life, adverse drug effects, and carer uplift (positive feelings about the care of the disabled person) and burden, together with total costs, were recorded at 4, 12, and 26 weeks. The primary outcome was change in aggression after 4 weeks' treatment, which was recorded with the modified overt aggression scale (MOAS). Analysis was by intention to treat. This study is registered as ISRCTN 11736448. Findings: 80 patients had adherence of 80% or more to prescribed drug. Aggression decreased substantially with all three treatments by 4 weeks, with the placebo group showing the greatest change (median decrease in MOAS score after 4 weeks=9 [95% CI 5-14] for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6·5 [5-14] for haloperidol, 65% from baseline; p=0·06). Furthermore, although no important differences between the treatments were recorded, including adverse effects, patients given placebo showed no evidence at any time points of worse response than did patients assigned to either of the antipsychotic drugs. Interpretation: Antipsychotic drugs should no longer be regarded as an acceptable routine treatment for aggressive challenging behaviour in people with intellectual disability.
dc.identifier.issn0140-6736
dc.identifier.urihttp://hdl.handle.net/1885/17245
dc.publisherLancet Publishing Group
dc.sourceLancet, The (UK edition)
dc.subjectKeywords: haloperidol; lorazepam; neuroleptic agent; placebo; risperidone; adult; aggression; agitation; article; Australia; behavior disorder; caregiver burden; clinical assessment; clinical trial; cognitive defect; controlled clinical trial; controlled study; dis
dc.titleRisperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in intellectual disability: randomised controlled trial
dc.typeJournal article
local.bibliographicCitation.issue9606
local.bibliographicCitation.lastpage63
local.bibliographicCitation.startpage57
local.contributor.affiliationTyrer, Peter, Canberra Hospital
local.contributor.affiliationOliver-Africano, Patricia C, Imperial College London
local.contributor.affiliationAhmed, Zed, University of Wales
local.contributor.affiliationBouras, Nick, King's College London
local.contributor.affiliationCooray, Sherva, Central North West London Foundation NHS Trust
local.contributor.affiliationDeb, Shoumitro, University of Birmingham
local.contributor.affiliationMurphy, Declan, Institute of Psychiarty
local.contributor.affiliationHare, Monica, University of Wales
local.contributor.affiliationMeade, Michael, Imperial College (London)
local.contributor.affiliationReece, Ben, Imperial College (London)
local.contributor.affiliationKramo, Kofi, Imperial College (London)
local.contributor.affiliationBhaumik, Sabyasachi, Leicester Frith Hospital
local.contributor.affiliationHarley, David, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationRegan, Adrienne, Harrow Primary Care NHS Trust
local.contributor.affiliationThomas, David, North East London Mental Health NHS Trust
local.contributor.affiliationRao, Bharti, Imperial College (London)
local.contributor.affiliationNorth, Bernard, Imperial College (London)
local.contributor.affiliationEliahoo, Joseph, Imperial College (London)
local.contributor.affiliationKaratela, Shamshad, University of Queensland
local.contributor.affiliationSoni, Anju, West London Mental Health NHS Trust
local.contributor.affiliationCrawford, Mike, Imperial College (London)
local.contributor.authoruidHarley, David, u3881428
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor119900 - OTHER MEDICAL AND HEALTH SCIENCES
local.identifier.ariespublicationu4222028xPUB1
local.identifier.citationvolume371
local.identifier.doi10.1016/S0140-6736(08)60072-0
local.identifier.scopusID2-s2.0-37449030577
local.identifier.thomsonID000252192600031
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Tyrer_Risperidone,_haloperidol_and_2008.pdf
Size:
143.38 KB
Format:
Adobe Portable Document Format